Cumberland Pharmaceuticals (NASDAQ:CPIX) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Trading Down 4.9 %

NASDAQ:CPIX opened at $1.55 on Tuesday. The company’s 50 day moving average price is $1.91 and its 200-day moving average price is $1.89. Cumberland Pharmaceuticals has a 52 week low of $1.43 and a 52 week high of $2.36. The company has a quick ratio of 1.11, a current ratio of 1.28 and a debt-to-equity ratio of 0.44. The stock has a market cap of $21.98 million, a price-to-earnings ratio of -3.52 and a beta of 0.16.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter. Cumberland Pharmaceuticals had a negative net margin of 15.87% and a positive return on equity of 6.84%. The firm had revenue of $9.35 million for the quarter.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new stake in shares of Cumberland Pharmaceuticals during the 3rd quarter valued at $142,000. Millennium Management LLC bought a new stake in Cumberland Pharmaceuticals in the 4th quarter valued at $46,000. Renaissance Technologies LLC increased its holdings in Cumberland Pharmaceuticals by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after acquiring an additional 38,100 shares during the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of Cumberland Pharmaceuticals by 27.8% in the 1st quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock worth $529,000 after buying an additional 40,949 shares during the last quarter. Hedge funds and other institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.